Pharmaceutical News

RSS

Camelid nanobody anti-SARS-CoV-2 drug candidates

In a research paper recently published in the journal eLife, researchers from several US institutions have developed a nanobody-based candidate drug that effectively prevents and suppresses severe SARS-CoV-2 infection in animals.

12 Aug 2021

Study finds cognitive safety of ketamine and esketamine for patients with treatment-resistant depression

Used for the treatment of depression that does not respond to standard antidepressant medications, the anesthesia drug ketamine – and the related drug esketamine, recently approved for depression treatment – has no important adverse effects on memory, attention, or other cognitive processes, concludes a systematic review of medical research in the September/October issue of Harvard Review of Psychiatry.

12 Aug 2021

FDA approves a new indication for chronic sleep disorder treatment

The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults.

12 Aug 2021

National academies’ report took pharma-friendly stance after millions in gifts from drugmakers

To several U.S. senators, it looked wasteful, even outrageous. Every year, taxpayers pay for at least $750 million worth of expensive pharmaceuticals that are simply thrown away. Companies ship many of the drugs in "Costco"-size vials, one lawmaker said, that once opened usually cannot be resealed or saved for other patients. Yet pharma gets paid for every drop.

12 Aug 2021

ACR applauds CMS' decision to withdraw the "Most Favored Nation" payment model for Part B drugs

The American College of Rheumatology today applauded the Centers for Medicare and Medicaid Services' decision to withdraw a proposed rule to implement the "Most Favored Nation" payment model for Part B drugs.

11 Aug 2021

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

A study measured neutralization of SARS-CoV-2 and vaccine responses in immunocompromised patients with systemic inflammatory diseases.

11 Aug 2021

Researchers quantify left-over COVID vaccine in used Pfizer-BioNTech vials

A new observational study, published on medRxiv* preprint server, has evaluated the unused residual Pfizer-BioNTech vaccine in vials. Bainbridge Prepares (BP), an organization consisting of community medical and non-medical volunteers, supported the research.

11 Aug 2021

CBD may reduce the adverse effects of anti-seizure drugs in people with epilepsy

Artisanal (non-pharmaceutical) cannabidiol (CBD) products have become popular in recent years for their apparent therapeutic effects. CBD — a naturally occurring compound of the cannabis plant legally derived from hemp — is used widely as a naturopathic remedy for a number of health conditions, including epilepsy and seizure disorders.

11 Aug 2021

A new promising target for broad-spectrum therapeutics against coronaviruses

A recent study by Canadian and US researchers demonstrates how frameshift signals of coronaviruses represent a viable target for developing novel therapeutics with broad-spectrum activity – not only against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other constituents of the coronavirus family. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

11 Aug 2021

Both mRNA vaccines protect against symptomatic disease with SARS-CoV-2 Delta variant

A new study demonstrates that the two mRNA vaccines have widely varying efficacies against the SARS-CoV-2 Delta variant.

10 Aug 2021

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

A new study reports a more rapid method of viral inactivation in an effort to increase the appeal of inactivated viral vaccines against the COVID-19 pandemic.

10 Aug 2021

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

A new study has explored a series of potential flavonoid inhibitors targeting 3CL protease of SARS-CoV.

9 Aug 2021

New study receives $33 million PCORI funding to compare anesthetic medications

More than 50,000 surgical patients undergo general anesthesia every day in the United States, but clinicians and scientists lack evidence indicating which types of anesthesia drugs result in the best outcomes for patients.

9 Aug 2021

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

New study describes SARS-CoV-2 ExoN enzyme that promotes antiviral resistance

A new study describes the structure of a crucial enzyme present in SARS-CoV-2.

8 Aug 2021

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

The recent US Food and Drug Administration (FDA) approval of aducanumab – which has the potential to treat Alzheimer's disease – may provide a proof of concept that can be rapidly improved upon, writes Dennis Selkoe in this Perspective.

6 Aug 2021

FDA approves an intravenous medication to treat patients with Pompe disease

Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.

6 Aug 2021

Pharmacies face extra audit burdens that threaten their existence

The clock was about to strike midnight, and Scott Newman was desperately feeding pages into a scanner, trying to prevent thousands of dollars in prescription payments from turning into a pumpkin.

6 Aug 2021

Study: Neglecting development of therapeutics may repeat history and replicate vaccine inequality

A new policy report released today by the global non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) highlights how the development of therapeutics has been relatively neglected in the global response to COVID-19 and warns that with the few treatment innovations available principally in high-income countries, we risk repeating history and replicating the vaccine inequality that has become a defining characteristic of this global pandemic.

6 Aug 2021

Pharmaceutical News

Camelid nanobody anti-SARS-CoV-2 drug candidates

Study finds cognitive safety of ketamine and esketamine for patients with treatment-resistant depression

FDA approves a new indication for chronic sleep disorder treatment

National academies’ report took pharma-friendly stance after millions in gifts from drugmakers

ACR applauds CMS' decision to withdraw the "Most Favored Nation" payment model for Part B drugs

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

Researchers quantify left-over COVID vaccine in used Pfizer-BioNTech vials

CBD may reduce the adverse effects of anti-seizure drugs in people with epilepsy

A new promising target for broad-spectrum therapeutics against coronaviruses

Both mRNA vaccines protect against symptomatic disease with SARS-CoV-2 Delta variant

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

New study receives $33 million PCORI funding to compare anesthetic medications

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

New study describes SARS-CoV-2 ExoN enzyme that promotes antiviral resistance

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

FDA approves an intravenous medication to treat patients with Pompe disease

Pharmacies face extra audit burdens that threaten their existence

Study: Neglecting development of therapeutics may repeat history and replicate vaccine inequality

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News